Medicare Negotiation And The Politics Of Drug Pricing

Medicare pricing decisions will become ‘highly politicized,’ Scott Gottlieb predicts. The former FDA commissioner and CMS official also believes the program should rely on outside health technology assessment groups, and he offers his opinions on how negotiation will (or won’t) change patent litigation.

List Of Negotiated Prices Will Be Published Shortly Before Election Day • Source: Shutterstock

The Centers for Medicare and Medicaid Services is likely to feel significant political pressure to prove the new Medicare price negotiation program produces big savings and so will seek deep discounts, especially with the first list of negotiated prices due to be released shortly before the 2024 Presidential elections.

President Biden’s 2024 federal budget proposal, with its plan to expand the price negotiation program to drugs even earlier in their lifecycle, is a clear signal that he continues to believe drug pricing is a winning political issue and will want to highlight his Administration’s work in that area

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet